Trial Profile
A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs Daclizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms EXTEND
- Sponsors Biogen
- 28 Oct 2022 Results (of studies ADVANCE, ASCEND, DECIDE and EXTEND) assessing Machine learning parcellation of multiple sclerosis lesions into texturally consistent super-voxels for lesion classification presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 01 Oct 2022 This trial has been completed in Poland (End Date: 24 Sep 2018) according to European Clinical Trials Database record.
- 31 Jul 2021 According to European Clinical Trials Database record, this study has been completed in Spain.